Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication

 
• By Jessica Merrill
  
Blue targets and three arrows reaching the center of the first one
Libtayo joins a competitive field with a new lung cancer indication • Source: Shutterstock (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer